Stock Screener App

무료 - Play StoreApp Store

설치하다 설치하다

DYN

$18.054.34%0.75

시간 외 거래: 18.050.00 0.00%

Dyne Therapeutics Inc (DYN)

Date: O: H: L: C: Vol:

Dyne Therapeutics Inc 주식(DYN)의 최신 뉴스

Form 4 Dyne Therapeutics Inc: Douglas Kerr (Head of R&D and CMO) For: 20 October By Investing.com - Investing.com South Africa

A 12,000-share option goes to Dyne Therapeutics (DYN) CMO Douglas Kerr alongside a stock award. - Stock Titan

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

At $16 a share, director Brian S. Posner buys 2,500 Dyne Therapeutics (DYN) shares. - Stock Titan

Dyne Therapeutics (NasdaqGS:DYN) Stock Forecast & Analyst Predictions - Simply Wall Street

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 - Investing News Network

Certain Restricted Stock Units of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026. - marketscreener.com

Certain Stock Options of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026. - marketscreener.com

New Dyne hires receive stock tied to 278,100 shares - Stock Titan

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Viking Therapeutics, Inc. - Common Stock (NQ: VKTX - The Chronicle-Journal

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dyne Therapeutics at Cantor conference: launch plans and pipeline expand By Investing.com - Investing.com Canada

Dyne Therapeutics at Cantor conference: launch plans and pipeline expand By Investing.com - Investing.com UK

(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Baird Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $26 - Moomoo

Wall Street Slashes Dyne Therapeutics Targets After Novartis DM1 Trial Failure - finance.biggo.com

DYN Maintained by Morgan Stanley -- Price Target Lowered to $36 - GuruFocus

Dyne Therapeutics Shares Plummet After Novartis Phase 3 Trial Failure - Intellectia AI

Dyne Therapeutics CMO Kerr Douglas Sells 5,035 Shares Between $18.88 and $24.35 (NASDAQ: DYN) - Kalkine Media

DYN Downgraded by JP Morgan -- Price Target Lowered to $10.00 - GuruFocus

Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says - Moomoo

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Yahoo Finance

DYN Maintains Rating by RBC Capital -- Price Target Lowered to $30 - GuruFocus

Dyne downgraded at J.P. Morgan on Novartis setback (DYN:NASDAQ) - Seeking Alpha

Dyne Therapeutics stock price target lowered to $30 by RBC Capital - Investing.com Canada

Dyne Therapeutics stock price target lowered to $30 by RBC Capital - Investing.com UK

Dyne Therapeutics falls 16% after Novartis DM1 trial failure raises doubts on RNA therapy success - Pluang

Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN) - Seeking Alpha

RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk - marketscreener.com

Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Nigeria

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Stocktwits

Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Australia

Dyne Therapeutics (DYN) officer plans $106K stock sale - Stock Titan

Dyne Therapeutics (Nasdaq: DYN) officer to sell 3,000 shares from RSUs - Stock Titan

Dyne Therapeutics (DYN) CCO’s tax sales leave 102,966 unvested RSUs - Stock Titan

Tax-driven stock sale by Dyne (DYN) medical chief - Stock Titan

Dyne Therapeutics (DYN) CEO sells shares to cover taxes - Stock Titan

Raymond James sets Dyne Therapeutics price targ... - Pluang

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling - Benzinga

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Yahoo Finance

Raymond James cuts Dyne Therapeutics price target on DM1 trial risk - Investing.com Nigeria

Raymond James cuts Dyne Therapeutics price target on DM1 trial risk - Investing.com Canada

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 at Upcoming Medical Meetings - Investing News Network

Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - rttnews.com

Dyne Therapeutics (DYN) Shares Plunge 28% After Novartis Phase I - GuruFocus

Dyne Therapeutics (DYN) Faces Market Pressure After Novartis DM1 - GuruFocus

Dyne Therapeutics (DYN) Faces Pressure After Novartis Trial Fail - GuruFocus

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga

DYN와(과) 유사한 종목

TARS$72.640.93%

CELC$69.723.95%

VKTX$26.092.76%

ELVN$44.830.45%

ACAD$20.570.49%

IRON$81.163.23%